Paysign, INC 8-K filings

Paysign, Inc. announced first quarter 2026 financial results, showcasing a 50.8% year-over-year revenue increase to $28.04 million, driven by significant growth in its patient affordability and plasma revenue segments, alongside substantial margin expansion.

Paysign, Inc. reported record full-year 2025 financial results, driven by a 40.5% revenue increase and significant margin expansion, primarily from its patient affordability solutions.

Paysign, Inc. announced strong third quarter 2025 financial results with record revenue and improved profitability, leading to an upward revision of its full-year 2025 guidance.

Paysign, Inc. has reached a settlement in multiple stockholder derivative actions, agreeing to implement significant corporate governance reforms and pay $607,500 in legal fees.

Paysign, Inc. reported record second quarter 2025 revenues of $19.08 million, a 33.1% increase year-over-year, driven by strong growth in its pharma patient affordability business.

Paysign, Inc. has announced a change in its independent registered public accounting firm from Moss Adams LLP to Baker Tilly US, LLP, effective June 3, 2025, due to a merger between the two accounting firms.

Paysign, Inc. held its annual meeting of stockholders on May 7, 2025, and all proposals, including the election of directors, approval of executive compensation, and ratification of the independent auditor, were approved.

Paysign's Q1 2025 results showcase significant revenue and Adjusted EBITDA growth, fueled by a surge in the patient affordability business.

Paysign announces a 23.5% revenue increase for 2024, driven by growth in patient affordability programs, and strategically acquires Gamma Innovation to bolster its technology offerings.

Paysign's third quarter 2024 saw a 23% revenue increase and a 20.6% rise in adjusted EBITDA, fueled by significant growth in its patient affordability programs.

Paysign, Inc. announced a significant increase in revenue and profitability for the second quarter of 2024, driven by strong growth in both its plasma and patient affordability businesses.

Paysign's first quarter of 2024 saw a significant 30% increase in revenue and a 135% jump in adjusted EBITDA, driven by strong performance in its patient affordability business.

Paysign, Inc. held its annual meeting of stockholders on May 3, 2024, where directors were elected and the selection of Moss Adams LLP as the independent auditor was ratified.

Paysign has received final court approval for a $3.75 million settlement in a securities class action lawsuit, with the payment covered entirely by the company's directors and officers insurance policy.

Paysign, Inc. announced a robust financial performance for 2023, highlighted by a 24% increase in revenue and a significant rise in net income.

Paysign, Inc. has updated its bylaws to include a description of the Chief Legal Officer's responsibilities and to reflect the company's name.

Paysign, Inc. has announced a series of executive leadership changes, including the appointment of Cosimo Cambi as Chief Operating Officer and Matt Lanford's transition to Chief Payments Officer.